Rubric Capital Exits Karyopharm Therapeutics Position

TL;DR

**Rubric Capital dumped all its Karyopharm shares, watch out!**

AI Summary

Rubric Capital Management LP, a Delaware-based investment firm, filed an amended SC 13G/A on February 12, 2024, indicating a significant change in its holdings of Karyopharm Therapeutics Inc. common stock. As of December 31, 2023, Rubric Capital reported owning 0 shares with both sole and shared voting and dispositive power, a decrease from its previous holdings. This matters to investors because it signals that a major institutional investor has completely exited its position in Karyopharm, potentially indicating a loss of confidence in the company's future prospects.

Why It Matters

This filing shows a major institutional investor, Rubric Capital Management LP, has sold all its shares in Karyopharm Therapeutics Inc., which could be a bearish signal for other investors.

Risk Assessment

Risk Level: medium — The complete divestment by an institutional investor like Rubric Capital could signal underlying concerns about Karyopharm's future performance or valuation, increasing investment risk.

Analyst Insight

A smart investor would consider this complete divestment by Rubric Capital Management LP as a potential red flag and conduct further due diligence into Karyopharm Therapeutics Inc.'s fundamentals and future prospects before making any investment decisions, especially if considering buying the stock.

Key Numbers

• 0 — Shares Beneficially Owned (Rubric Capital Management LP's current beneficial ownership in Karyopharm Therapeutics Inc. as of December 31, 2023.)
• 48576U106 — CUSIP Number (Identifies the specific class of securities (Common Stock, $0.0001 par value) of Karyopharm Therapeutics Inc.)

Key Players & Entities

• Rubric Capital Management LP (company) — the reporting person that filed the SC 13G/A
• Karyopharm Therapeutics Inc. (company) — the subject company whose securities are being reported
• Delaware (company) — state of organization for Rubric Capital Management LP
• December 31, 2023 (date) — the date of the event requiring the filing
• 0 (dollar_amount) — number of shares beneficially owned by Rubric Capital Management LP

Forward-Looking Statements

• Karyopharm Therapeutics Inc. stock price may experience downward pressure due to the institutional divestment. (Karyopharm Therapeutics Inc.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.0001 — OF CLASS OF SECURITIES: Common stock, $0.0001 par value per share (the " Common

Filing Documents

• tm245464d11_sc13ga.htm (SC 13G/A) — 74KB
• 0001104659-24-013556.txt ( ) — 75KB

(a)

Item 1(a). NAME OF ISSUER: The name of the issuer is Karyopharm Therapeutics Inc. (the " Issuer "). Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: The Issuer’s principal executive offices are located at 85 Wells Avenue, 2nd Floor, Newton, MA, 02459. Item 2(a). NAME OF PERSON FILING: This (i) Rubric Capital Management LP (" Rubric Capital "), the investment adviser to certain investment funds and/or accounts (collectively, the " Rubric Funds ") that held the shares of Common Stock (as defined in Item 2(d) below) reported herein; and (ii) David Rosen (" Mr. Rosen "), Managing Member of Rubric Capital Management GP LLC, the general partner of Rubric Capital. The foregoing persons are hereinafter sometimes collectively referred to as the " Reporting Persons ." The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein. Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE: The address of the principal business office of each of the Reporting Persons is 155 East 44th St, Suite 1630, New York, NY 10017. Item 2(c). CITIZENSHIP: Rubric Capital is a Delaware limited partnership. Mr. Rosen is a citizen of the United States of America. Item 2(d). TITLE OF CLASS OF SECURITIES: Common stock, $0.0001 par value per share (the " Common Stock "). Item 2(e). CUSIP NUMBER: 48576U106 CUSIP No. 48576U106 13G/A Page 5 of 7 Pages Item 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13d-1(b) OR 13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a) Broker or dealer registered under Section 15 of the Act, (b) Bank as defined in Section 3(a)(6) of the Act, (c) Insurance Company as defined in Section 3(a)(19) of the Act, (d) Investment Company registered under Section 8 of

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of our knowledge and belief, each of the undersigned certifies that the information set forth in this DATED: February 12, 2024 RUBRIC CAPITAL MANAGEMENT LP By: /s/ Michael Nachmani Name: Michael Nachmani Title: Chief Operating Officer /s/ David Rosen DAVID ROSEN

View Full Filing

View this SC 13G/A filing on SEC EDGAR